CINECA IRIS Institutional Research Information System

GALIMBERTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 42.844
AS - Asia 18.210
EU - Europa 14.842
SA - Sud America 3.168
Continente sconosciuto - Info sul continente non disponibili 974
AF - Africa 670
OC - Oceania 38
Totale 80.746
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 39.322
SG - Singapore 5.359
IT - Italia 5.217
CN - Cina 5.188
HK - Hong Kong 3.248
CA - Canada 3.156
BR - Brasile 2.612
SE - Svezia 2.401
VN - Vietnam 1.681
DE - Germania 1.191
BG - Bulgaria 1.145
PL - Polonia 1.033
GB - Regno Unito 838
TR - Turchia 710
FR - Francia 674
RU - Federazione Russa 595
FI - Finlandia 568
UA - Ucraina 444
IN - India 391
JP - Giappone 390
KR - Corea 292
CI - Costa d'Avorio 211
CH - Svizzera 202
BD - Bangladesh 187
AR - Argentina 161
MX - Messico 124
IQ - Iraq 112
EC - Ecuador 99
NL - Olanda 99
ID - Indonesia 89
BE - Belgio 88
SN - Senegal 87
AT - Austria 85
ZA - Sudafrica 84
PK - Pakistan 83
UZ - Uzbekistan 82
SA - Arabia Saudita 75
CO - Colombia 68
VE - Venezuela 58
CR - Costa Rica 54
ES - Italia 53
MA - Marocco 53
PY - Paraguay 53
JM - Giamaica 47
KE - Kenya 47
NG - Nigeria 44
EG - Egitto 39
PH - Filippine 38
CL - Cile 34
MY - Malesia 31
UY - Uruguay 31
PE - Perù 30
AU - Australia 29
CZ - Repubblica Ceca 29
IE - Irlanda 29
IL - Israele 27
AZ - Azerbaigian 25
NI - Nicaragua 24
LT - Lituania 23
TN - Tunisia 22
TT - Trinidad e Tobago 22
JO - Giordania 21
OM - Oman 20
RO - Romania 20
AE - Emirati Arabi Uniti 19
GR - Grecia 19
KZ - Kazakistan 19
BJ - Benin 18
BO - Bolivia 18
DO - Repubblica Dominicana 18
EU - Europa 16
PS - Palestinian Territory 16
HN - Honduras 15
NP - Nepal 15
ET - Etiopia 14
DZ - Algeria 13
PT - Portogallo 13
AL - Albania 10
DK - Danimarca 10
IR - Iran 10
LB - Libano 10
TH - Thailandia 10
BB - Barbados 9
HU - Ungheria 9
PA - Panama 9
NZ - Nuova Zelanda 8
RS - Serbia 8
SC - Seychelles 8
SV - El Salvador 8
BH - Bahrain 7
BY - Bielorussia 7
GT - Guatemala 7
PR - Porto Rico 7
TW - Taiwan 7
GE - Georgia 6
KG - Kirghizistan 6
AM - Armenia 5
EE - Estonia 5
KW - Kuwait 5
MD - Moldavia 5
Totale 79.683
Salva come PNG Salva come JPEG
Città #
Ashburn 3.879
Hong Kong 3.201
Woodbridge 3.154
Singapore 2.990
Fairfield 2.510
Dallas 2.491
Ann Arbor 2.393
Montreal 2.357
San Jose 2.062
Houston 2.027
Serra 2.009
Chandler 1.810
Santa Clara 1.730
Milan 1.256
Beijing 1.185
Shanghai 1.155
Sofia 1.137
Seattle 1.106
New York 878
Wilmington 870
Cambridge 823
Council Bluffs 729
Boardman 683
Princeton 630
Los Angeles 595
Ottawa 593
Jacksonville 574
Lawrence 454
Medford 437
Ho Chi Minh City 436
Lauterbourg 433
Hefei 424
Izmir 424
Tokyo 342
Nanjing 315
Seoul 275
Hanoi 256
Florence 233
São Paulo 232
Des Moines 231
London 222
Abidjan 210
Istanbul 203
Munich 202
Dearborn 198
Buffalo 196
Redondo Beach 185
Rome 179
San Diego 174
Dong Ket 169
Bern 159
Nanchang 155
Helsinki 139
Redwood City 120
Chicago 119
Frankfurt am Main 113
Atlanta 104
Jüchen 98
Bremen 94
Pisa 92
Orem 90
Hebei 88
Lancaster 88
Dakar 87
Brussels 86
Changsha 86
Shenyang 84
Rio de Janeiro 81
Phoenix 78
Tashkent 75
Kunming 73
Ogden 69
Turku 68
Fuzhou 67
Columbus 65
Nuremberg 63
Vienna 63
Toronto 62
Da Nang 61
The Dalles 60
Denver 58
San Francisco 57
Belo Horizonte 56
Brooklyn 55
Düsseldorf 54
Guangzhou 52
Curitiba 51
Washington 51
Boulder 49
Jiaxing 48
Westminster 48
Dhaka 46
Chennai 45
Haiphong 45
Porto Alegre 45
Norwalk 44
Warsaw 44
Hangzhou 42
Nairobi 42
Pune 42
Totale 54.918
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.426
Diagnostic applications of nuclear medicine: Multiple myeloma 766
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 446
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 287
Multidisciplinary Evaluation Improves Efficacy and Safety of Iron Chelation Therapy with Deferasirox in MDS Elderly Patients 276
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA 273
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 264
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 254
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 252
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 247
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 242
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 241
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 237
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 236
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 233
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 232
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 229
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 228
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 225
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 224
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 222
An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience 221
Autoimmune diseases and myeloid hematological disorders: a possible pathogenetic relationship 221
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 220
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 220
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 219
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 218
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 216
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 215
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 213
Panobinostat for the treatment of acute myelogenous leukemia 213
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 213
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 212
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 211
Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study 210
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 210
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 209
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 209
Clinical Applications of Nuclear Medicine: Multiple Myeloma 208
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 208
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience 207
Characterization of Ph-negative abnormal clones emerging during imatinib therapy 207
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 207
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 207
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 205
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 204
Unexpected cardiotoxicity in haematological bortezomib treated patients 204
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 203
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 203
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 203
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 202
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 200
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 200
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 199
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 199
The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma 199
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 199
Diagnostic Applications of Nuclear Medicine: Leukemias 199
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 199
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 198
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 197
Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Eng. 2007 Oct 5 196
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 196
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 196
SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTIC CELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITOR BORTEZOMIB. 195
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 195
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 195
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 195
SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. 195
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. 195
Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine 195
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 194
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 194
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 193
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 193
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 193
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 192
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure 192
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 191
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 191
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 191
Precision medicine in lymphoma by innovative instrumental platforms 191
Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography. 189
MDS: An Integrated Workup for a Correct Diagnosis 189
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 189
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 189
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 189
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 188
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 188
Good manufacturing practice-grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation 188
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 188
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 186
Unusual morphology in a case of large granular cell leukemia 185
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 185
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 185
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 184
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 184
BORTEZOMIB IS ABLE TO INACTIVATE NF-KB AND DOWN-REGULATE WT1 GENE IN P39 CELL LINE: A POSSIBLE USE IN HIGH-RISK MYELODYSPLASTIC SYNDROMES? 184
Morphological analysis of phenotype MDR cell expression: morphofunctional correlations 184
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 184
Totale 24.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 223.204
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 223.204
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.922 0 0 141 344 919 658 158 235 440 150 363 1.514
2022/20235.772 910 812 383 550 568 698 54 457 873 45 356 66
2023/20248.104 603 555 557 365 713 798 230 106 66 3.358 186 567
2024/202514.818 66 562 123 786 1.150 1.255 1.366 946 1.483 1.980 1.617 3.484
2025/202617.663 912 2.322 2.790 1.925 1.560 1.617 2.341 793 891 1.395 819 298
2026/20275.880 1.127 3.028 1.725 0 0 0 0 0 0 0 0 0
Totale 80.746